Key result
Mitral valve repair for active endocarditis was associated with lower hospital mortality and higher 15-year overall survival compared to replacement.
Why the study?
Does mitral valve repair improve survival and reduce reoperation compared to mitral valve replacement in patients with active native mitral valve endocarditis?
Cohort (n=192)
No
Does mitral valve repair improve survival and reduce reoperation compared to mitral valve replacement in patients with active native mitral valve endocarditis?
An early, repair-oriented surgical approach for active mitral valve endocarditis yields high reparability rates, good long-term durability, and low recurrence rates.
Answers are grounded in this paper and cite their sources.
Supports repair when feasible in active native mitral endocarditis; leaves open need for randomized confirmation of survival benefit.
OBJECTIVES: We retrospectively analysed our 20-year experience on surgical treatment of native mitral valve (MV) endocarditis in a single institution using an early and repair-oriented surgical approach. METHODS: From August 1991 to December 2015, 192 consecutive patients underwent MV surgery for active endocarditis. Of these, 81% (n = 155) had MV repair while 19% had MV replacement. In-hospital and late outcomes were analysed in the 2 groups and in the subgroups of repair with and without the use of a patch. Study end points were overall survival, MV reoperation and valve-related events. The median follow-up was 122 and 146 months in the repair and replacement groups, respectively. RESULTS: Patients undergoing MV replacement were significantly older with more severe preoperative comorbidities and clinical conditions compared to patients undergoing MV repair (P < 0.05). When the repair and replacement groups were compared, hospital mortality was 11.6% and 29.7%, respectively (P = 0.006); at 15 years, overall survival was 57 ± 6% and 36 ± 12%, respectively (P = 0.03); freedom from MV reoperation was 81 ± 6% and 73 ± 18%, respectively (P = 0.46); linearized rate of recurrent endocarditis was 0.1% and 2.4%, respectively. Fifteen-year freedom from reoperation was 75.4 ± 8.6% vs 92 ± 4.5% in the patch versus no-patch repair subgroups, respectively (P = 0.33). CONCLUSIONS: Active MV endocarditis remains a life-threatening disease. In experienced centres, an early and repair-oriented surgical approach can achieve relatively high reparability rates with good long-term durability of the repair and a very low recurrence rate of endocarditis. Patients could benefit from MV repair even if patch material is necessary to repair the valve.
No takes yet. Share an insight, caveat, or question.
Solari et al. (2018) conducted a cohort in active infective mitral valve endocarditis (n=192). Mitral valve repair vs. Mitral valve replacement was evaluated on 15-year overall survival (p=0.03). Mitral valve repair for active endocarditis was associated with lower hospital mortality and higher 15-year overall survival compared to replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: